108 related articles for article (PubMed ID: 29571732)
1. Induction of MEK/ERK activity by AZD8055 confers acquired resistance in neuroblastoma.
Xu DQ; Toyoda H; Qi L; Morimoto M; Hanaki R; Iwamoto S; Komada Y; Hirayama M
Biochem Biophys Res Commun; 2018 May; 499(3):425-432. PubMed ID: 29571732
[TBL] [Abstract][Full Text] [Related]
2. Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma.
Fujishita T; Kojima Y; Kajino-Sakamoto R; Taketo MM; Aoki M
Oncogene; 2017 Nov; 36(46):6480-6489. PubMed ID: 28759045
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor effect of AZD8055 against neuroblastoma cells in vitro and in vivo.
Xu DQ; Toyoda H; Yuan XJ; Qi L; Chelakkot VS; Morimoto M; Hanaki R; Kihira K; Hori H; Komada Y; Hirayama M
Exp Cell Res; 2018 Apr; 365(2):177-184. PubMed ID: 29499203
[TBL] [Abstract][Full Text] [Related]
4. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
5. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.
Chresta CM; Davies BR; Hickson I; Harding T; Cosulich S; Critchlow SE; Vincent JP; Ellston R; Jones D; Sini P; James D; Howard Z; Dudley P; Hughes G; Smith L; Maguire S; Hummersone M; Malagu K; Menear K; Jenkins R; Jacobsen M; Smith GC; Guichard S; Pass M
Cancer Res; 2010 Jan; 70(1):288-98. PubMed ID: 20028854
[TBL] [Abstract][Full Text] [Related]
6. Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors.
Ewald F; Nörz D; Grottke A; Hofmann BT; Nashan B; Jücker M
Invest New Drugs; 2014 Dec; 32(6):1144-54. PubMed ID: 25152244
[TBL] [Abstract][Full Text] [Related]
7. Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation.
Cope CL; Gilley R; Balmanno K; Sale MJ; Howarth KD; Hampson M; Smith PD; Guichard SM; Cook SJ
J Cell Sci; 2014 Feb; 127(Pt 4):788-800. PubMed ID: 24363449
[TBL] [Abstract][Full Text] [Related]
8. The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro.
Li Q; Song XM; Ji YY; Jiang H; Xu LG
Biochem Biophys Res Commun; 2013 Nov; 440(4):701-6. PubMed ID: 24103749
[TBL] [Abstract][Full Text] [Related]
9. The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8.
Shi JJ; Chen SM; Guo CL; Li YX; Ding J; Meng LH
Acta Pharmacol Sin; 2018 Aug; 39(8):1338-1346. PubMed ID: 29345254
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
11. Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC).
Zhang Y; Jia QA; Kadel D; Zhang XF; Zhang QB
Med Sci Monit; 2018 May; 24():2735-2743. PubMed ID: 29720580
[TBL] [Abstract][Full Text] [Related]
12. AZD8055 Exerts Antitumor Effects on Colon Cancer Cells by Inhibiting mTOR and Cell-cycle Progression.
Chen Y; Lee CH; Tseng BY; Tsai YH; Tsai HW; Yao CL; Tseng SH
Anticancer Res; 2018 Mar; 38(3):1445-1454. PubMed ID: 29491070
[TBL] [Abstract][Full Text] [Related]
13. Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126.
Eppstein AC; Sandoval JA; Klein PJ; Woodruff HA; Grosfeld JL; Hickey RJ; Malkas LH; Schmidt CM
J Pediatr Surg; 2006 Jan; 41(1):252-9. PubMed ID: 16410143
[TBL] [Abstract][Full Text] [Related]
14. Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: a potential mechanism of therapeutic limitation of mTOR inhibitor.
Iida S; Miki Y; Ono K; Akahira J; Nakamura Y; Suzuki T; Sasano H
Mol Cell Endocrinol; 2012 Mar; 350(1):99-106. PubMed ID: 22178087
[TBL] [Abstract][Full Text] [Related]
15. Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma.
Cirstea D; Santo L; Hideshima T; Eda H; Mishima Y; Nemani N; Mahindra A; Yee A; Gorgun G; Hu Y; Ohguchi H; Suzuki R; Cottini F; Guichard SM; Anderson KC; Raje N
Mol Cancer Ther; 2014 Nov; 13(11):2489-500. PubMed ID: 25172964
[TBL] [Abstract][Full Text] [Related]
16. mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer.
Wei F; Zhang Y; Geng L; Zhang P; Wang G; Liu Y
Int J Mol Sci; 2015 Feb; 16(2):3267-82. PubMed ID: 25654224
[TBL] [Abstract][Full Text] [Related]
17. Discontinuing MEK inhibitors in tumor cells with an acquired resistance increases migration and invasion.
Nörz D; Grottke A; Bach J; Herzberger C; Hofmann BT; Nashan B; Jücker M; Ewald F
Cell Signal; 2015 Nov; 27(11):2191-200. PubMed ID: 26210887
[TBL] [Abstract][Full Text] [Related]
18. Suppression of miR-19b enhanced the cytotoxic effects of mTOR inhibitors in human neuroblastoma cells.
Chen Y; Tsai YH; Tseng BJ; Pan HY; Tseng SH
J Pediatr Surg; 2016 Nov; 51(11):1818-1825. PubMed ID: 27492819
[TBL] [Abstract][Full Text] [Related]
19. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.
Willems L; Chapuis N; Puissant A; Maciel TT; Green AS; Jacque N; Vignon C; Park S; Guichard S; Herault O; Fricot A; Hermine O; Moura IC; Auberger P; Ifrah N; Dreyfus F; Bonnet D; Lacombe C; Mayeux P; Bouscary D; Tamburini J
Leukemia; 2012 Jun; 26(6):1195-202. PubMed ID: 22143671
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
